Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BridgeBio Pharma (BBIO) Total Debt: 2019-2024

Historic Total Debt for BridgeBio Pharma (BBIO) over the last 6 years, with Dec 2024 value amounting to $738.9 million.

  • BridgeBio Pharma's Total Debt rose 69.73% to $740.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $740.4 million, marking a year-over-year increase of 69.73%. This contributed to the annual value of $738.9 million for FY2024, which is 65.50% up from last year.
  • BridgeBio Pharma's Total Debt amounted to $738.9 million in FY2024, which was up 65.50% from $446.4 million recorded in FY2023.
  • BridgeBio Pharma's Total Debt's 5-year high stood at $738.9 million during FY2024, with a 5-year trough of $93.9 million in FY2020.
  • Moreover, its 3-year median value for Total Debt was $446.4 million (2023), whereas its average is $538.8 million.
  • Data for BridgeBio Pharma's Total Debt shows a peak YoY soared of 358.84% (in 2021) over the last 5 years.
  • Yearly analysis of 5 years shows BridgeBio Pharma's Total Debt stood at $93.9 million in 2020, then spiked by 358.84% to $430.8 million in 2021, then climbed by 0.06% to $431.0 million in 2022, then rose by 3.59% to $446.4 million in 2023, then spiked by 65.50% to $738.9 million in 2024.